• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trial Listings
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Clinical Trial Listings
  • Advertise
  • COVID-19
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Analysis: DCTs Are Proving Their Benefits, Significantly Cutting Down Trial Costs

Analysis: DCTs Are Proving Their Benefits, Significantly Cutting Down Trial Costs

January 24, 2022

Decentralized trials (DCTs) can provide up to 14 times return on investment for phase 3 trials due to accelerating trial timelines, a new Tufts study has found.

In phase 2 trials, DCTs typically saved one to three months’ worth of time and delivered a net benefit up to five times greater than investment costs.

“On average, the financial returns to drug sponsors from shorter development times, lower clinical trial screen failure rates and fewer clinical trial protocol amendments associated with DCTs substantially exceeded the costs of investing in DCT technologies,” said Joseph DiMasi, director of economic analysis at Tufts’ Center for the Study of Drug Development (CSDD).

The study analyzed data from more than 150 DCTs on the Medable platform using an expected net present value based on trial cycle time, cost and performance benchmarks, in addition to some conservative assumptions about the impact of DCTs and their investment costs.

CSDD has declined to release detailed data from the study prior to it undergoing peer review. When peer review is complete, Tufts will share detailed findings on the financial savings DCTs can provide.

 

To view more CenterWatch Weekly stories, click here.

Upcoming Events

  • 25Apr

    Effective Root Cause Analysis and CAPA Investigations for Drugs, Devices and Clinical Trials

  • 26Apr

    FDA’s New Laws and Regulations: What Drug and Biologics Manufacturers Need to Know

  • 27Apr

    Califf’s FDA, 2023 and Beyond: Key Developments, Insights and Analysis

  • 17May

    2023 WCG Avoca Quality Consortium Summit

  • 21May

    WCG MAGI Clinical Research Conference – 2023 East

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • tablet

    Digital Intake Platforms Effective as Source of Trial Information, Survey Shows

  • Diversity-360x240.png

    Site Spotlight: EmVenio Research Takes to the Road to Promote Trial Diversity

  • Five Ws

    Consider the Five ‘W’s to Understand Potential Participants

  • QandA-360x240.png

    Perspectives from Smaller-Sized CROs: Q&A with Cheryle Evans

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell or Share My Data

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing